The LATE-MT randomized controlled trial demonstrates that mechanical thrombectomy can improve 90-day functional outcomes in anterior-circulation large vessel occlusion stroke patients presenting 24 to 72 hours after symptom onset, compared to standard medical care. However, the procedure carries significant risks, including increased mortality rates and symptomatic intracranial hemorrhage. While thrombectomy's benefits within earlier time windows have been well established, extending treatment beyond 24 hours shows promise for patients with slower disease progression. Despite functional improvements, clinicians must carefully weigh the therapeutic advantages against elevated adverse event rates when considering late thrombectomy interventions. These findings from the prospective, multicenter trial were presented at the 2026 European Stroke Organisation Conference, providing critical evidence for decision-making in extended-window stroke treatment protocols.

Ischemic stroke remains a significant cause of mortality and disability worldwide, with conventional interventions constrained by limited therapeutic windows and blood-brain barrier penetration challenges. This comprehensive review examines nanotechnology's potential across four critical stroke management stages: prevention, neuroprotection, revascularization, and adjunctive therapy. The authors emphasize the value of staged nanomedicine interventions, from controlled drug delivery during prevention to extending acute treatment windows and enhancing therapeutic efficacy. By systematically addressing challenges at each management stage, nanotherapeutics offer promising solutions to overcome limitations of traditional thrombolysis and mechanical thrombectomy approaches, potentially improving patient outcomes and reducing long-term disability associated with ischemic stroke.

Phosphorylcholine coating represents a biomimetic surface treatment that replicates the outer membrane structure of human cells, offering significant advantages for medical device applications. This innovative coating technology substantially enhances biocompatibility while reducing adverse biological reactions. Key benefits include enhanced hemocompatibility through minimized platelet adhesion and reduced thrombosis risk, a diminished inflammatory response by suppressing immune cell activation, and exceptional long-term stability under physiological conditions through covalent bonding. These properties make phosphorylcholine-coated devices particularly valuable for blood-contacting applications and implantable medical systems, where biocompatibility and durability are critical for optimal clinical outcomes.

This article reviews contemporary strategies and mechanisms for developing medical anticoagulation coatings applied to blood-contacting devices. Medical polymers, valued for their thermal resistance, corrosion resistance, and flexibility, serve as foundational materials for cardiovascular stents, hemodialysis membranes, and catheters. However, thrombus formation on device surfaces remains a significant clinical challenge. The research systematically examines advanced approaches to construct anticoagulant surface coatings, addressing a critical need in biomaterials science. These innovations aim to enhance the biocompatibility and safety of implanted medical devices by preventing unwanted blood clotting, ultimately improving patient outcomes in cardiovascular and therapeutic applications.

Flow-diverting stents (FDs) for the treatment of cerebrovascular aneurysms are revolutionary. However, these devices require systemic dual antiplatelet therapy (DAPT) to reduce thromboembolic complications. Given the risk of ischemic complications as well as morbidity and contraindications associated with DAPT, demonstrating safety and efficacy for FDs either without DAPT or reducing the duration of DAPT is a priority. The former may be achieved by surface modifications that decrease device thrombogenicity, and the latter by using coatings that expedite endothelial growth. Biomimetics, commonly achieved by grafting hydrophilic and non-interacting polymers to surfaces, can mask the device surface with nature-derived coatings from circulating factors that normally activate coagulation and inflammation.

Endovascular thrombectomy (EVT) has emerged as an effective treatment option. Unfortunately, interfacility transfers to thrombectomy-capable centers often delay treatment time. The direct to angio suite (DTA) pathway reduces interfacility transfer time by foregoing the emergency department at the thrombectomy-capable center and directing patients immediately to the angio suite. Up to 22% of patients transferred under the DTA pathway will not have a large vessel occlusion on cerebral angiography or will experience significant neurological improvement, obviating the need for EVT. This study evaluated predictive factors associated with EVT under the DTA protocol.

Endothelialization, the formation of endothelial cell layers on blood-contacting medical devices, is critical for vascular implants such as stents and grafts. This biological response creates a natural, non-thrombogenic interface that enhances device performance and biocompatibility. Alta Biomed's PzF thin-film coating technology offers a promising surface modification strategy to optimize endothelialization while addressing concerns regarding thrombus formation, vascular healing, and coating integrity. Multiple factors influence endothelialization success, including device material, surface chemistry, coating selection, geometry, and local flow conditions. Strategic consideration of these elements during device development is essential for improving clinical outcomes.

The benefit of IV thrombolysis (IVT) before thrombectomy in patients with anterior-circulation large-vessel occlusion (LVO) due to carotid artery dissection (CAD) remains uncertain. We aimed to evaluate the safety and efficacy of IVT in this specific population in clinical practice.

Bioresorbable materials represent a rapidly advancing class of biomaterials designed to perform therapeutic or diagnostic functions before safely degrading into physiologically compatible products within the body. Unlike permanent implants, these materials eliminate the need for secondary surgical removal procedures, thereby reducing patient risk, healthcare costs, and long-term complications from foreign material retention. However, designing effective bioresorbable materials presents significant challenges, requiring materials to maintain mechanical stability during their functional lifetime while demonstrating predictable and controllable degradation patterns. Recent advances in materials science, nanotechnology, and biomedical engineering continue to address these complex requirements, promising to substantially enhance the safety and functionality of medical devices across numerous clinical applications.

Multifunctional implantable hydrogels represent a significant advancement in biomedical innovation, serving as intelligent platforms for diverse clinical applications. These sophisticated biomaterials integrate multiple functionalities within a single construct, enabling controlled drug delivery, tissue engineering, and biosensing capabilities. Their smart design allows for responsive behavior to environmental stimuli, enhancing therapeutic efficacy while minimizing adverse effects. This emerging technology demonstrates considerable potential in regenerative medicine and personalized treatment approaches, positioning hydrogels as transformative tools in modern healthcare delivery and disease management strategies.

Remote teleoperation of endovascular intervention robots represents a transformative approach in minimally invasive vascular procedures, enabling clinicians to perform complex interventions from distant locations. This systematic review examines the evidence surrounding teleoperated endovascular robotic systems, emphasizing technical feasibility, communication infrastructure requirements, and clinical outcomes. By enabling remote delivery of specialized vascular care, these systems promise to reduce clinician radiation exposure and physical strain while expanding access to emergency interventions such as mechanical thrombectomy for acute stroke. The review synthesizes findings from relevant studies to identify current capabilities, limitations, and research gaps in this emerging field, establishing a foundation for future development and clinical implementation of remote endovascular intervention technologies.

There is a significant decrease in the number of adherent CD61 +ve platelets on nickel titanium surfaces coated with the HPC-II coating compared to uncoated surfaces. The coating can be successfully applied to the wires of flow diverters. The results of this study are promising with regard to the development of new anti-thrombogenic endovascular devices.

Tranexamic acid (TXA) is a synthetic lysine analog widely used as an antifibrinolytic agent. Large randomized trials have demonstrated life-saving benefits when TXA is administered early in acute hemorrhage, but results regarding prophylactic administration have been conflicting, and several trials have not shown improved clinical outcomes. The mechanisms underlying this discrepancy remain incompletely understood. Objectives: To investigate the molecular and structural mechanisms that determine TXA efficacy in purified fibrin clots under conditions mimicking therapeutic versus prophylactic administration.

Endologix, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics. The deal for the Pounce thrombectomy system, which is designed for non-surgical removal of thrombi and emboli from peripheral arteries, closed Monday. Financial details of the sale weren’t disclosed. A “core group” of Surmodics employees who support the Pounce system are also moving over to Endologix as part of the deal, the company said in a May 19 press release.

The guidelines are introduced by NMPA Center of Medical Device Evaluation (CMDE). It is not legally binding but highly recommended by regulatory authorities. The revision plan will not only impact the new product registration but also renewals and modifications. It involves type testing, clinical, registration review guidelines, technical guidelines, e.g., Real World Study design, and documentation guidelines, e.g., Indication for Use (IFU) writing. NMPA issues new or updated guidelines throughout the year. Given their importance in understanding what the NMPA reviewers are looking for, it is essential that manufacturers keep up to date with the guidelines that are latest to their specific products. One source to get updates on these guidelines is through our complimentary monthly news roundup that you can opt in from our website www.ChinaMedDevice.com

Mechanical thrombectomy can lead to an improvement in 90-day functional outcome compared to standard medical care in anterior-circulation large vessel occlusion (LVO) stroke patients presenting 24–72 hours after symptom onset, as per the findings of the LATE-MT randomised controlled trial (RCT). However, within the trial, thrombectomy was also associated with increased rates of mortality, symptomatic intracranial haemorrhage (ICH) and other clinically relevant adverse events.

A pioneering study led by Dr. Youxiang Li at Beijing Tiantan Hospital, Capital Medical University, together with Dr. Wei Feng from Songyuan Jilin Oilfield Hospital, offers a robust analysis of treatment outcomes for BTAs in the modern era defined by flow diverter innovations. Published in the March 2026 issue of the Chinese Neurosurgical Journal, this important research fills a notable void in neurosurgical literature by systematically evaluating the efficacy and safety of minimally invasive endovascular treatments in a sizable cohort despite the aneurysms’ rarity.

The strategy of administering intra-arterial (IA) thrombolysis immediately after thrombectomy in patients with acute ischemic stroke has come under renewed scrutiny after results from the TECNO trial showed no clear improvement in reperfusion rates with this approach.The idea of giving a dose of IA thrombolysis immediately after thrombectomy in patients with acute ischemic stroke has become more uncertain, with the results of a new trial showing no clear benefit on reperfusion rates using this approach.These results are in contrast to the previous CHOICE-2 trial, first presented earlier this year at the International Stroke Conference, and now published in JAMA. CHOICE-2 showed positive results in terms of good functional outcomes with an IA thrombolysis strategy, although this was dampened by an increased mortality rate.

Patients in the study underwent a range of minimally invasive procedures, including simple coiling, stent-assisted coiling, and flow diverters, devices designed to redirect blood flow away from the aneurysm. Stent-assisted coiling was the most common treatment, used in just over half of cases, while flow diverters were employed in nearly 30 %, particularly for more complex or larger aneurysms.The results were largely positive. At follow-up imaging, about 72 % of patients achieved complete aneurysm occlusion, meaning the aneurysm was fully sealed off, while nearly 19 % had near-complete occlusion. Clinically, about 89 % of patients had favorable outcomes, defined as minimal or no disability.

Large vessel occlusion (LVO) stroke is associated with a high risk of permanent disability. There are no reliable tools providing periprocedural information on clot characteristics, such as composition and length, that may impact first pass effect, which has been shown to improve functional outcomes. In the first study of a novel technology, we evaluated whether the Clotild Smart Guidewire System (Clotild), an impedance-based device, can provide in situ information on clot characteristics during a mechanical thrombectomy procedure.